Press release content from Business Wire. The AP news staff was not involved in its creation.
Ethics Approval Granted for Open Orphan’s COVID-19 Human Challenge Study Model
February 17, 2021 GMT
LONDON--(BUSINESS WIRE)--Feb 17, 2021--
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces the world’s first COVID-19 characterization study has received approval from a specially convened Research Ethics Committee (REC). This news follows the announcement on October 20, 2020 of Open Orphan subsidiary hVIVO’s contract with the UK Government to develop a COVID-19 human challenge study model.